TriangleNCT02489903 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From start of treatment through death for up to 64 months from Start of Treatment.
What was measured
From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.
Groups in this outcome
RRx-001 + Platinum Doublet (A01-09)
4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy
RRx-001 + Platinum + RRx-001 (A10)
RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).
Investigator's Choice (A10)
Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity
| Group | Source count |
|---|---|
| RRx-001 + Platinum Doublet (A01-09) | 89 |
| RRx-001 + Platinum + RRx-001 (A10) | 10 |
| Investigator's Choice (A10) | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRx-001 + Platinum Doublet (A01-09) | 6.85 | Not reported | 5.80 | 8.62 | Not reported |
| RRx-001 + Platinum + RRx-001 (A10) | 7.6 | Not reported | 5.00 | NA | insufficient number of participants with events |
| Investigator's Choice (A10) | 7.5 | Not reported | 3.00 | NA | insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.80
- upper Limit
- 8.62
- value
- 6.85
- comment
- insufficient number of participants with events
- group Id
- OG001
- lower Limit
- 5.00
- upper Limit
- NA
- value
- 7.6
- comment
- insufficient number of participants with events
- group Id
- OG002
- lower Limit
- 3.00
- upper Limit
- NA
- value
- 7.5
- denoms
- counts
- group Id
- OG000
- value
- 89
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 2
- units
- Participants
- description
- From the time from enrollment until the time of death from any cause or last follow-up. Patients will be followed clinically as outlined in the treatment schedule and will be followed off study for death.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy
- id
- OG000
- title
- RRx-001 + Platinum Doublet (A01-09)
- description
- RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).
- id
- OG001
- title
- RRx-001 + Platinum + RRx-001 (A10)
- description
- Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity
- id
- OG002
- title
- Investigator's Choice (A10)
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- From start of treatment through death for up to 64 months from Start of Treatment.
- title
- Overall Survival
- type
- PRIMARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice